Welcome to Otsuka America Pharmaceutical, Inc. Otsuka America Pharmaceutical, Inc. (OAPI) is all about people. It is the people of OAPI who make this an exciting and fulfilling environment - one which fosters an atmosphere of creativity and opportunity. And it is people to whom we are dedicated: patients who use our products, healthcare professionals who treat these patients, residents of our community, and colleagues with whom we serve. As a company, we recognize the challenges and opportunities to be successful in an ever-evolving healthcare environment. OAPI has established a solid reputation for providing quality products, engaging well-trained professionals, and contributing to an industry that is undergoing significant and rapid changes. We have brought together a diverse group of highly-skilled individuals who have commercialized ABILIFY®  (aripiprazole) Tablets1 and PLETAL®  (cilostazol) Tablets2 and have developed strong collaborations with Bristol-Myers Squibb, which co-develops and co-promotes ABILIFY, and other companies such as Santarus, Inc. with whom OAPI co-promotes ZEGERID®  (omeprazole/sodium bicarbonate)3. We have also positioned ourselves for the commercialization of several other important products. It is an exciting time for us as an organization because we know that our business is growing, we have tremendous potential, and patients will benefit from our success. 1 Please see FULL PRODUCT INFORMATION including Boxed WARNINGS for ABILIFY. 2 Please see FULL PRODUCT INFORMATION including Boxed WARNINGS for PLETAL. 3 Please see FULL PRODUCT INFORMATION for ZEGERID. Search OAPI: Font Size: Privacy Statement

* OAPI, OPDC, and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established by OPC in the U.S. in 1989